Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Summit Therapeu ADR 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 USA

www.summittxinc.com P: 650-460-8308

Description:

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

Key Statistics

Overview:

Market Capitalization, $K 3,081,692
Enterprise Value, $K 3,110,262
Shares Outstanding, K 701,980
Annual Sales, $ 0 K
Annual Net Income, $ -614,930 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -36,570 K
EBIT, $ -609,640 K
EBITDA, $ -607,590 K
60-Month Beta -1.13
% of Insider Shareholders 83.70%
% of Institutional Shareholders 4.61%
Float, K 114,423
% Float 16.30%
Short Volume Ratio 0.55

Growth:

1-Year Return 167.68%
3-Year Return -24.57%
5-Year Return 148.02%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -117.86%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.05 on 05/01/24
Latest Earnings Date N/A
Earnings Per Share ttm -0.16
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 16.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

SMMT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -125.07%
Return-on-Assets % -51.02%
Profit Margin % 0.00%
Debt/Equity 1.29
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 64.47
Book Value/Share 0.11
Interest Coverage -20.02
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar